Former US President Donald Trump has revealed a structured plan to impose substantial tariffs on imported generic medicines, a move intended to compel pharmaceutical companies to relocate manufacturing operations to the United States. The policy, detailed in a post on Truth Social, gives companies a two-year grace period before duties begin to escalate, potentially reaching 200%.
Phased Tariff Implementation
Under the proposed plan, generic drug imports will face a zero-percent tariff from August 1, 2026, through July 2028, maintaining current arrangements. Following this window:
- From August 2028 for one year, the tariff will increase to 100%.
- From August 2029 onwards, the tariff will be raised further to 200%.
Trump explicitly framed this policy as a measure to “RESHORE Generic Pharmaceutical Production into America,” adding that it serves as a penalty for companies that do not establish manufacturing facilities within the specified timeframe. He clarified that existing policies for patented, branded, and innovative drugs will remain unaffected.
Significant Implications for India's Pharma Sector
This announcement directly impacts India, which stands as the largest exporter of generic drugs to the United States. According to a Global Trade Research Initiative report, India exported pharmaceuticals worth USD 9.7 billion to the US in 2025, representing 38% of its total global pharma exports of USD 25.8 billion.
India, often recognized as the "pharmacy of the world," is a crucial supplier of affordable generic medications for various conditions, including hypertension, diabetes, cancer, infectious diseases, and mental health. The American market is central to the economic viability of India's pharmaceutical industry.
Potential Responses and Economic Impact
The new tariff structure presents a critical challenge for Indian pharmaceutical firms, many of which already have operations within the US. These companies will need to evaluate their strategies, potentially choosing to expand their domestic US manufacturing capacity, absorb the increased tariff costs, or pass these expenses on to American consumers and insurers. The decisions made by these firms will ultimately determine the real-world economic impact of this ambitious policy.